Vivek Kumar
Add to Bookmarks
E-mini NASDAQ-100 Index

Hologic, a global leader in women’s health, said on Thursday that it will acquire the fast-growing Finnish French biotechnology company Mobidiag Oy for about $795 million, including a cash payment of nearly $714 million for Mobidiag’s equity, and net debt of about $81 million.

The acquisition is expected to close early in the fourth quarter of fiscal 2021.

Know where the Market is headed? Take advantage now with 

Trading Derivatives carries a high level of risk to your capital and you should only trade with money you can afford to lose. Trading Derivatives may not be suitable for all investors, so please ensure that you fully understand the risks involved, and seek independent advice if necessary. A Product Disclosure Statement (PDS) can be obtained either from this website or on request from our offices and should be considered before entering into a transaction with us. Raw Spread accounts offer spreads from 0.0 pips with a commission charge of USD $3.50 per 100k traded. Standard account offer spreads from 1 pips with no additional commission charges. Spreads on CFD indices start at 0.4 points. The information on this site is not directed at residents in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

In 20202, Mobidiag generated nearly $42 million of revenue. Hologic expected to invest in assay development to drive the growth of the Novodiag platform. As a result, the acquisition is expected to be about $0.10 dilutive to Hologic’s non-GAAP earnings per share in fiscal 2022, slightly dilutive in 2023, and accretive thereafter, the company said in the press release.

Hologic’s shares, which surged about 40% in 2020, rose just over 1% to $73.58 so far this year.

Analyst Comments

“Mobidiag was not inexpensive, but the asset offers an entry point into the rapidly growing acute-care segment and is very consistent with Hologic’s strategy to expand MDx throughout and beyond the COVID-19 pandemic,” noted David Lewis, equity analyst at Morgan Stanley.

Hologic has developed two molecular diagnostic tests for COVID-19 which are driving significant financial contribution. The company’s 3-4% end-market growth rates likely limit long-term growth potential to an extent, but COVID-19 Dx cash flow could allow material reinvestment or tuck-ins to shift underlying growth higher. We see increased M&A activity as a requirement to shift the WAGMR higher and drive the multiple.”


Hologic Stock Price Forecast

Seven analysts who offered stock ratings for Hologic in the last three months forecast the average price in 12 months of $96.00 with a high forecast of $110.00 and a low forecast of $91.00.

The average price target represents a 30.47% increase from the last price of $73.58. Of those seven analysts, six rated “Buy”, one rated “Hold” while none rated “Sell”, according to Tipranks.

Morgan Stanley gave the base target price of $84 with a high of $96 under a bull scenario and $56 under the worst-case scenario. The firm gave an “Equal-weight” rating on the medical technology company’s stock.

Several other analysts have also updated their stock outlook. Hologic had its target price boosted by Jefferies to $110 from $106. Jefferies Financial Group currently has a buy rating. Robert W. Baird upped their price target to $91 from $84 and gave the stock a buy rating.

Moreover, Zacks Investment Research downgraded Hologic to a hold rating from a buy and set a $79 price target on the stock. Argus upped their price target to $100 from $85.

Check out FX Empire’s earnings calendar

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker